David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO), filed a Form 4 on November 9, 2026, disclosing the purchase of 5,000 shares of common stock in an underwritten public offering at $5.00 per share.

Key Highlights

  • Transaction: Hochman acquired 5,000 shares of Orchestra BioMed common stock on November 9, 2026, at a price of $5.00 per share.
  • Source of purchase: According to the filing, the shares were purchased in an underwritten public offering of the issuer at the public offering price of $5.00 per share.
  • Direct holdings after transaction: Hochman directly beneficially owns 1,067,463 shares of common stock following the reported transaction.
  • Indirect holdings: The filing also reports 437,916 shares held indirectly through the DPH 2008 Trust, plus additional shares held through four other named trusts: 2,000 shares each via the Solomon Ascher Hochman 2019 Trust, the Hannah Hochman 2019 Trust, and the Judah Herman Hochman 2019 Trust, and 3,140 shares via the NSH 2008 Family Trust.
  • Role: Hochman is identified in the filing as Chief Executive Officer and Chairperson, as well as a Director.

Hochman's Public Offering Purchase and Beneficial Ownership at Orchestra BioMed

The Form 4 filed by David P. Hochman on November 9, 2026 covers a single non-derivative transaction. According to the filing, Hochman acquired 5,000 shares of Orchestra BioMed Holdings, Inc. common stock (par value $0.0001 per share) on November 9, 2026, using transaction code "P" (indicating an open market or direct purchase). The filing states these shares were purchased in an underwritten public offering at the public offering price of $5.00 per share, with an indirect ownership stake recorded through the DPH 2008 Trust.

Following the reported transaction, the filing discloses that Hochman directly beneficially owns 1,067,463 shares of common stock. In addition to those direct holdings, the filing lists indirect beneficial ownership of 437,916 shares through the DPH 2008 Trust, 2,000 shares through the Solomon Ascher Hochman 2019 Trust, 2,000 shares through the Hannah Hochman 2019 Trust, 2,000 shares through the Judah Herman Hochman 2019 Trust, and 3,140 shares through the NSH 2008 Family Trust. No derivative securities transactions were reported in this filing.

The form was signed by Andrew Taylor as Attorney-in-Fact on behalf of Hochman and filed on November 9, 2026. Orchestra BioMed Holdings, Inc. is listed on NASDAQ under the symbol OBIO, and Hochman's address of record is listed as c/o Orchestra BioMed Holdings, Inc., 150 Union Square Drive, New Hope, Pennsylvania 18938.

What Was Disclosed

Hochman, Orchestra BioMed's CEO and Chairperson, reported purchasing 5,000 shares at $5.00 each in a public offering on November 9, 2026. After the transaction, the filing shows direct holdings of 1,067,463 shares, plus additional shares held indirectly through five named trusts.